Clinical Trials

Healing Through Psychedelic-Assisted Psychotherapies

Clinical Trials Search for Unconventional Treatments

Psychedelics offer the potential to revolutionize the mental healthcare industry as we know it. Mydecine was Mydecine was founded to discover, analyze, and bring psychedelic and functional compounds to global markets to support mental health and addiction solutions. Our clinical trials focus on psychedelic-assisted psychotherapy for post-traumatic stress disorder (PTSD) and nicotine dependency.

Our Current Clinical Trials

Seamless Phase 2/3 Clinical Trial

Seamless Phase 2/3 Clinical Trial

Utilizing Psilocybin for Smoking Cessation

We will be launching a seamless phase 2/3 clinical trial in early 2022 in partnership with Johns Hopkins University led by Dr. Matthew Johnson. Dr. Johnson, is Professor of Psychiatry and Behavioral Sciences at Johns Hopkins. He is one of the world’s most published scientists on the human effects of psychedelics, and has conducted seminal research in the behavioral economics of drug use, addiction, and risk behavior. The planned study evaluates the administration of MYCO-001 with a structured smoking cessation treatment program in nicotine dependent individuals.

Study to Help Treat PTSD in Veterans

Study to Help Treat PTSD in Veterans

Even the Strong Need Mental Health Support

We are planning a Phase 2A clinical trial focusing on PTSD in veterans, EMS, and front-line workers. We have global test sites currently approved at Leiden University, University of Alberta, Royal Ottawa Hospital, and Western Ontario University. In addition to that, we are finalizing several U.S. sites including Boston, Los Angeles, and San Francisco.

Large-scale Microdose Study

Large-scale Microdose Study

Big Solutions Through Low Doses

We are currently supporting a large-scale microdose study co-sponsored by the National Institute for Health Research at Imperial College of London with Dr. David Erritzoe, a member of our Medical, Scientific, and Technology Advisory Board.

First-of-its-kind Microdose Study

First-of-its-kind Microdose Study

Innovating the Way Psychedelics are Used

We are conducting a first-of-its-kind microdose study at Macquarie University in Australia. Our Medical, Scientific, and Technology Advisory Board member Dr. Vince Polito is leading this ongoing study.